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Abstract 
 
Nephropathic Cystinosis is a rare autosomal recessive disease characterised by raised 
lysosomal levels of cystine in the cells of all organs. It is treated by the six-hourly oral 
administration of the aminothiol, cysteamine, which has an offensive taste and smell.  In 
an attempt to reduce this frequency and improve the treatment, cysteamine-containing PEG 
suppositories were prepared and evaluated for dissolution and stability.  The results 
demonstrated that cysteamine release was complete after 30 minutes, and that there was 
uniform drug distribution within the formulations.  Twelve-month stability tests 
highlighted a potential incompatibility between some excipients, although stability was 
demonstrated for the cysteamine suppositories up to six months.  These suppositories may 
provide a useful alternative to the current oral therapy for cystinosis. 
 
Keywords: Cystinosis, Rectal Formulations, PEG. 
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1.0 Introduction 
Nephropathic Cystinosis is a rare genetic disease characterised primarily by extremely high 
intracellular levels of the amino acid cystine, electrolyte imbalance, proximal renal tubular 
dysfunction (Fanconi syndrome) and general failure to thrive (1,2).  The accumulation of 
cystine as crystals in most tissues leads to the progressive dysfunction of multiple organs 
(3).  The incidence of cystinosis is one in 100,000 – 200,000 live births, and affects 
approximately 2000 patients in the world, although there are believed to be many more 
cases undiagnosed (2,4).  Some infants will die due to dehydration and electrolyte 
imbalance from Fanconi syndrome without diagnosis (5).  In the US alone there are 500-
600 reported cases, with between 20 and 40 born each year (5).   
 
Cystinosis is categorised as a Lysosomal Storage Disorder (LSD), which is a group of 
progressive disorders that share multi-organ failure as an endpoint (3,5).  As with all LSDs, 
no signs of abnormality are displayed at birth; the first symptoms of glomerular dysfunction 
begin to appear at around 6-12 months of age (2).  Without treatment most children will 
reach end-stage renal failure by age nine (5), and grow at 50-60% of the expected rate.  By 
the age of eight an untreated child with cystinosis will be the height of a 4-year old (5), 
and, if inadequately treated, may not reach four feet in height.   
 
The condition is caused by a defect in the CTNS gene.  This is gene codes for a 367 amino-
acid lysosomal transport protein called Cystinosin. In healthy cells, the amino acid cystine 
is transported into the cytoplasm of the cell for processing. In cystinosis however, it 
accumulates within the lysosomes to levels of 10-1000 times those seen in healthy cells, 
whereupon it crystallises from solution, causing cell death and organ failure (6).  This 
crystallisation is widespread throughout the majority of the tissues and organs in the body 
(7).  If left untreated symptomatic deterioration leads to death by the second decade of life 
(8).   
 
The treatment for cystinosis involves the administration of the amino thiol cysteamine, 
which is used therapeutically in the bitartrate form as CystagonTM.  With early and diligent 
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therapy, cystinosis patients can prevent or delay most of the non-renal complications and 
extend their lives into a fourth or fifth decade, live independently and some women have 
borne children (5,9).  The renal damage is continuous however, and decline is inevitable 
(5). 
 
Cysteamine causes a range of side effects, and this is largely due to the high dose which is 
required as much of the drug is lost to first-pass metabolism (9).  High blood levels must 
be achieved, as a large proportion of the administered drug will bind to circulating proteins, 
and cannot be up taken by the cells (10,11).  Patients should aim to take their dose at regular 
6-hour intervals for the treatment to work effectively, as the plasma half-life of cysteamine 
is 1.88 hours (7), with blood levels peaking at 1h, and rapidly declining thereafter (5).  This 
is a lifelong commitment and requires the patient to wake in the middle of the night (9).  
The drug has a foul taste and smell akin to rotten eggs, which regularly induces vomiting 
after ingestion (9).  In approximately 10-15% of patients this can be severe enough to halt 
therapy (5).  Cysteamine and its metabolites are excreted in breath and sweat, and this is 
also an issue, especially when the child enters education.  Cysteamine has the potential to 
cause potentially serious stomach irritations such as gastric acid hypersecretion, reverse 
peristalsis and bile reflux, and 97% of patients report gastrointestinal symptoms (12,13), 
which in many patients is severe enough to significantly limit therapy (14,15,16).  
Compliance can therefore be a major barrier to effective treatment, and lead to significant 
morbidity.   
 
The rectal route of administration can largely avoid the phenomenon of first-pass effect.  
This results from one of the three rectal veins draining into the hepatic system, while the 
middle and lower veins bypass this and drain directly into the systemic circulation.  If the 
suppository is positioned correctly, the drug should not be subjected to the first pass effect.  
This potentially allows a smaller dose to be administered, thereby reducing or eliminating 
some of the unpleasant side effects.  They may also be beneficial for treating conditions in 
infancy, when capsules are difficult to administer, or when the oral route is compromised.  
Rectal formulations are useful tools, particularly in a case such as this where the taste and 
side effects renders the task of swallowing a tablet very unpleasant and foreboding 
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1.1 Aims 
 
Formulation science may provide a way to improve the current medication, significantly 
improving the lives of sufferers and those who care for them.  By eliminating the taste and 
frequency of administration through alternative dosage forms, ease of administration of 
cysteamine could be improved.  The aim of this work was to develop alternative 
formulations of cysteamine which could reduce or eliminate some of the side effects 
experienced using the current oral capsule, thereby improving the quality of life for those 
affected.  An improvement in the ease of administration of cysteamine to infants and young 
children was a central objective, therefore suppositories were investigated.  By avoiding 
the first-pass metabolism of cysteamine, a lower dose should be achievable, while the taste 
and upper-gastric side effects should be eliminated.  A study conducted by Van’t Hoff and 
co-workers was previously undertaken where a cysteamine-loaded suppository gel, for use 
in cystinosis, was evaluated. However this rectal formulation was eliminated before 
cysteamine absorption was completed (17).  
 
 
2.0 Materials and methods 
2.1 Materials 
 
Cysteamine hydrochloride and polyethylene glycol grades 400, 600, 1000, 1500, 3000, 
4000, 6000, 8000 and 14000 were obtained from Sigma.  Witepsol W35 was obtained from 
Gattefosse (St-Priest, France).  Gelucire 39/01 was purchased from Sasol GmbH (Witten, 
Germany).  Poloxamer F68 was bought from BASF SE (Ludwigshafen, Germany).  
Ellman’s Reagent, 5,5'-dithiobis(2-nitrobenzoate) (DTNB) was purchased from Molekula 
(Gillingham, UK).  Tris buffer and Tween 80 were bought from Fisher. 
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2.2 Synthesis of N, N-(Bis-L-phenylalanyl)cystamine bistrifluoroacetate,  
(Phenylalanine conjugate). 
 
Cysteamine does not possess a chromophore and therefore is UV transparent, thus 
monitoring its release from formulations is very difficult.  Initially, a phenylalanine 
conjugate was developed to tag the molecule, allowing quantitative determination of 
release of the active from the dosage form via UV spectroscopy (figure 1).  Cystamine, the 
oxidized disulphide of cysteamine was used in the synthesis.  The phenylalanine conjugate 
was subsequently replaced with cysteamine hydrochloride with DTNB detection (see 
dissolution studies). 
 
 
Figure 1: N, N-(Bis-L-phenylalanyl)cystamine bistrifluoroacetate,  (Phenylalanine 
conjugate) 
  
To a stirring solution of cystamine dihydrochloride (1g, 0.00444 moles) in anhydrous 
dichloromethane (20 cm3) at room temperature, 1,8-diazabicycloundec-7-ene (1.33 ml, 
0.0089 moles) was added.  The reaction mixture was then stirred at room temperature for 
1 hour.  To this was added butoxycarbonyl-L-phenylalanineN-hydroxysuccinimide ester 
(3.22 g, 0.0089 moles).  After thin layer chromatographic analysis, the reaction mixture 
was then partitioned between dichloromethane (20 cm3) and water (50 cm3).  The 
dichloromethane extracts were washed with water (3 x 50 cm3) and dried over magnesium 
sulphate. The resultant solution was applied to a silica gel chromatography column (4 x 30 
cm3) prepared with dichloromethane.  The column was initially eluted with 100% DCM 
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followed by 2% graduations of methanol, with the protected compound eluting at 9:1 DCM 
: methanol. 
The protected compound was dissolved in trifluoroacetic acid (5 cm3) at room temperature.  
After 3.5 hours, the trifluoroacetic acid was removed by co-evaporation with ethanol (3 x 
20mls).  Trituration with diethyl ether followed by filtration and drying (vacuum oven at 
50°C) gave the target compound as an off – white solid. Yield: 42%. 
 
Found: 
Mass spectroscopy: m/z 447.2 (100%); 224.4 (50%).  M: C22H32N4O2S22+; Exact Mass: 
448.2.   
NMR: All analyses were undertaken using a Bruker Topspin Ultrashield 400MHz 
(Massachusetts, USA).   1HNMR spectrum (CD3OD) (400MHz)  : 2.55 (m, CH2-Ar, 2H); 
2.95 (m, CHH-S2, 1H); 3.05 (m, CHH-S2, 1H); 3.25 (m, α-CH, 1H); 3.3 (m, NH-CHH, 
1H); 3.45 (m, NH-CHH, 1H); 3.95 (t, NH, 1H); 7.25 (m, Ar-H’s, 5H). 13CNMR spectrum 
(CD3OD) (400MHz)  : 37.7(CH2-S2); 38.8 (β-CH2); 39.5 (NH-CH2); 55.8 (α-CH); 128.9 
(Ar-CH); 130.1 (Ar-CH); 130.5 (Ar-CH); 135.6 (Ar-CH); 169.7 (C=O). Melting range: 
100-104°C  
 
2.3 Suppository preformulation and manufacture  
To allow for wastage, the weight of eight suppositories was calculated for a six-form 
mould.  The calibration value was calculated for each mould, and the displacement value 
was calculated for each drug.  The bases were weighed accurately on a Mettler AE50 
analytical balance, along with the active.  The bases were heated and blended together, 
before addition of either cysteamine or phenylalanine conjugate.  This mix was then 
thoroughly stirred and the resultant liquid poured into a mould and allowed to cool.  The 
tops were then trimmed with a spatula, and the final forms removed from the mould, 
bottled and labeled (BP, 2005).  The surfactant Tween 80 was used in some formulations 
to ensure the fatty bases were sampled accurately from the dissolution medium. 
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Lipophilic bases, hydrophilic bases and blends of different PEG grades were examined 
for optimum characteristics.  As 10 mg kg-1was used for previous rectal delivery of 
cysteamine, 60mg was used as a nominal value (17).  Until further tests are carried out in 
vivo, the correct dose cannot be determined.  
Suppository hardness was tested on an Erweka TBH28 hardness tester (Heusenstamm, 
Germany).  A hardness value of at least 1.8-2kg is considered acceptable for unmedicated 
suppositories (18).  If the inert suppository blend produced unsatisfactory results beyond 
this range, no further testing was performed.  The suppositories with the best 
characteristics, based on hardness tests and appearance were selected for further testing.  
 
 
2.4 Dissolution studies  
 
Dissolution tests were performed in a six-chambered Sotax CH-4123 dissolution bath 
(Basel, Switzerland).  The dissolution test method followed the standard BP test for 
suppositories: one suppository in a stainless-steel basket, rotating at 100 rpm in a 1L beaker 
containing medium at 37°C, sampling at 5 minute intervals for 1 hour (BP 2005 Edition).  
The dissolution medium was altered depending on the active used.  The release was 
measured by UV spectroscopy.  The samples were returned to the bath after analysis.  
Suppositories containing the phenylalanine conjugate were initially tested in distilled 
water, using UV absorbance at 256 nm corresponding to the λmax. 
Cysteamine hydrochloride release can be measured via free sulphydryl concentration 
through the use of DTNB (Ellman’s Reagent, 5-(3-Carboxy-4-nitrophenyl)disulphanyl-2-
nitrobenzoic acid). Basically, one mole of DTNB reacts with one mole of cysteamine to 
release one mole of 2-nitro-5-thiobenzoate (NTB).  The concentration of NTB and hence 
the concentration of cysteamine can be determined using UV-Vis spectroscopy. 
Calibration measurements, using an analytical wavelength of 440 nm, gave a linear 
response, R2=0.9991.  The dissolution medium was 90% deionised water and 10% 1M Tris 
buffer solution at pH8.  Due to the susceptibility of DTNB to photolysis when in solution, 
the tank was surrounded by aluminum foil and protected from light. 
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The Higuchi equation was used to determine the rate-order of the drug release.  A result 
below 0.45 is indicative of Fickian diffusion (19). 
 
 
2.5 Active dispersion studies 
 
In a suppository, there is a possibility that the tip might contain more drug than the rest of 
the form due to gravitational settling (18).  To ensure uniform drug loading, three separate 
areas of the suppository were sampled and compared using a DSC Q100 Differential 
Scanning Calorimeter (TA instruments Delaware, USA) and the experiment carried out in 
triplicate.  Coupled with this, DSC studies of suppositories were carried out, to determine 
the thermal characteristics of each suppository blend.  
 
 
2.6 Stability tests  
 
Stability studies were conducted over a 12-month period.  Upon manufacture (T0), the 
suppositories were stored under three different environmental conditions in order to 
determine their stability; a refrigerator at 4C and 8 %RH (Relative Humidity), a store 
containing a desiccator with saturated sodium hydrogen sulphate solution at 20°C and 52 
%RH (20), and an Environmental Test Chamber (Copely, Nottingham, England) set at 
30C and 75 %RH (21).  These conditions were selected to simulate cold storage, typical 
home storage and accelerated testing.  As the suppositories had low melting points, it was 
decided to reduce the commonly used accelerated temperature from 37C to 30C.  The 
temperature in each of the storage areas was monitored daily.  DSC and IR spectroscopy 
were undertaken every week for one month, every month for 3 months, and subsequently 
every 3 months for 12 months, and compared with the T0 results (21).    IR Spectroscopy, 
was undertaken using a Nicolet IS10 IR from Thermo Scientific (Fisher, UK) with a Smart 
iTR attachment and a diamond HATR (horizontal attenuated total reflectance). Thiol 
groups absorb at a wavenumber of 2600 to 2550cm-1, while disulphides absorb between 
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620 and 600cm-1(22).  These measurements were used as the basis for the comparisons 
made between samples.  
Samples of uniformly less than 10mg were placed in a standard aluminium pan for DSC 
analysis.  The DSC was set to a heat-cool-heat cycle, where the sample was equilibrated 
at 0°C, then heated to 100°C at 10°C per minute, equilibrated at 100°C, then cooled at 
10°C per minute to 0°C, before being heated again to 100°C at 10°C per minute.   
 
 
3.0 Results and discussion 
 
The final three suppositories selected for further characterisation were blend “A” (40% 
PEG 8000, 60% PEG 600), blend “B” (40% PEG 14000, 60% PEG 600) and blend “C” 
(PEG 1500) (table 1).  There is a large variation in release onset in forms A, B and C, which 
is illustrated by large standard deviation values.  T100 for PEG blends A, B and C were 
observed at 20, 45 and 60 minutes respectively (n = 5-9).  PEG blend C released the 
phenylalanine conjugate more slowly than PEG blends A and B.  This may be due to the 
greater hardness of blend C (table 2). 
 
Table 1. A summary of the batches made and their characteristics. 
Suppository 
batch 
 
Composition 
(% w/w) 
Hardness 
without 
active 
Hardness 
including  
active 
(Cysteamine 
HCl) 
Appearance 
A PEG 8000 40% 
PEG 600 60% 
 
19N, 1.94 kg 9N, 0.92 kg Uniform white 
B PEG 14000 40% 
PEG 600 60% 
 
17N, 1.73 kg 12N, 1.22 kg Uniform white 
C PEG 1500 
100% 
30N, 3.06 kg 27N, 2.75 kg Opaque 
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Table 2. Summary of phenylalanine conjugate release studies 
Percentage 
release 
Time to release phenylalanine conjugate (minutes, ± SD) 
PEG blend A PEG blend B PEG blend C Gelucire Witepsol 
10% 2 (± 7.1) 2 (± 6.3) 3 (± 5.1) 0.5 0.5 
25% 5 5 9.5 1 1 
50% 7 7.5 12.5 2 2 
75% 10 (± 5.6) 10 (± 5.4) 17 (± 8.6) 2.5 2.5 
100% 20 (± 0.6) 45 (± 0.8) 59 (± 0.7) 4.5 4.5 
 
 
The fatty bases Witepsol and Gelucire produced a more homogenous blend and melted 
instantly (data not shown), whereas the PEG bases produced a more prolonged dissolution 
profile and dissolved more slowly over time (figure 2).  It was decided to continue studies 
using PEG bases only, as they produced a more prolonged release of 20-60 minutes 
compared to 2 minutes for Witepsol and Gelucire.  This slower dissolution of the PEGs 
allows the drug to be in contact with the rectum for longer where it is more likely to be 
absorbed into the body. A sudden melt over 2 minutes would increase the chances of the 
drug being lost through expulsion. 
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Figure 2.  Percentage release of the phenylalanine conjugate from PEG Blends A, B and C 
over time  
(n = 7, 9 and 6 respectively) 
 
Figure 3 illustrates the release of the active from the three suppository bases over time.  
Cysteamine hydrochloride was used as the active, formulated into suppository bases PEG 
blends A, B and C. 
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Figure 3.  Percentage release of cysteamine from PEG Blends A, B and C over time (n = 
6, 5 and 5 respectively). 
 
All three PEG blends containing cysteamine hydrochloride as the active displayed more 
reproducible profiles than dissolution using the phenylalanine conjugate.  The PEG bases 
should dissolve at the same rate in every replicate, and this may have been due to non-
uniform drug loading of the phenylalanine conjugate.  The phenylalanine conjugate was 
developed initially to allow release from the dosage forms, to be monitored 
spectrophotometrically.  It should be noted that cysteamine hydrochloride is a difficult drug 
to formulate.  At room temperature it undergoes oxidation to a disulphide form, cystamine, 
which itself has been shown to deplete cells of cystine but which is not licensed for use 
(5,23,24).  Cysteamine is also extremely hygroscopic and deliquescent.  However, the 
introduction of DTNB as a quantitative reagent allowed measurement of cysteamine 
directly.  A summary of the release times obtained is shown in table 3.  The data produced 
using Ellman’s reagent demonstrated excellent reproducibility (average standard error of 
the mean for PEG Blend: A – 0.39, B – 0.58, C – 0.14).   
14 
 
 
Table 3. Summary of cysteamine hydrochloride release studies 
Percentage release Time to release cysteamine hydrochloride (minutes) 
PEG blend A PEG blend B PEG blend C 
10% 1.75 2.5 1.75 
25% 5 6.5 4.5 
50% 9 10 7 
75% 13 15 9.5 
100% 26 26 17 
 
 
3.1 Active dispersion studies 
 
To ensure cysteamine hydrochloride was evenly dispersed throughout the suppository, 
samples were taken from three separate portions of the suppository and analysed using 
DSC (figure 4).  There was minimal difference between the tip, edge and middle sections 
of the suppository suggesting a uniform dispersion of active within the PEG suppository.   
 
 
Figure 4.  Section comparison of the melt phase between the tip, middle and edge areas of 
the PEG Blend A suppository containing cysteamine hydrochloride. 
 
15 
 
3.2 Stability tests 
 
The temperature and relative humidity in each of the three storage chambers were 
monitored continuously throughout a 12 month period.  The average results obtained are 
shown in table 4. 
 
Table 4.  Average temperatures and relative humidities in each storage chamber, with 
standard deviations (n = 3). 
 Refrigerator Store ETC* 
Average temperature 3.7°C (± 0.8) 20.3°C (± 1.9) 29.9°C (± 1.0) 
Average relative humidity 9.2% (± 0.3) 52% 76.4% (± 2.0) 
*Environmental Test Chamber 
 
 
3.3 DSC results: T0, T6 months, T12 months comparison. 
 
The thermal properties of the suppositories were assessed at time zero (T0), six (T6) and 
twelve (T12) months storage at 4°C/8 %RH, 21°C/52 %RH and 30°C/75 %RH.  The main 
melting endotherm of PEG in the broad range of 30-60°C was analysed in terms of the 
onset of the melt (Tonset), the peak temperature (Tmax) and the total enthalpy (W/g).  
Selected data are presented in table 5 as an increase or decrease in temperature and 
enthalpy compared with samples at T0.  An exemplary thermogram of PEG blend C 
suppositories at T0, T6 and T12 is also included (figure 5). 
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Figure 5. An Exemplary thermogram of PEG blend C supositories. 
 
Reference to the data in table 5 indicates significant changes to Tonset and Tmax for aged 
samples of PEG blend A at 30°C, blend B at 21°C and blend C at both 21 and 30°C. 
Suppositories stored at 4°C demonstrated less certain variation in Tonset and Tmax as may 
have been expected for samples stored at this refrigerated temperature. Although the bulk 
of the temperature variations were considered to be within the error of measurement for 
DSC analyses, it is clear that changes to the degree of crystallinity at the higher storage 
temperatures had occurred.  A depletion in the crystalline character of PEG suppositories 
may be expected based on lengthy exposure to high humidity and temperature, 
exacerbated by the hygroscopic (deliquescent) nature of contained cysteamine 
hydrochloride.  There is some evidence of increased crystallinity for PEG blend B stored 
at 21°C, considered as a ‘lamellar thickening’ of ordered ethylene oxide units (25), but 
the overall data set suggests a decrease in the molecular order of cysteamine containing 
PEG suppositories at elevated temperatures over time.  Increased enthalpies for the melt 
transition in all samples are a consequence of a broadened endotherm, symptomatic of 
increased disorder in crystalline domains rather than increased order which would 
produce clear increases to values of Tonset and Tmax and a sharpening of the melting event.  
Such changes are not evident. 
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Table 5.  DSC analysis data of selected suppository samples over time (n = 3). 
Suppository 
sample 
Time zero 
             Tonset  (°C) 
            H (J/g) 
Tmax (°C) 
T 6 months 
           Tonset  (°C) 
           H (J/g) 
Tmax (°C) 
T 12 months 
Tonset  (°C) 
H (J/g) 
Tmax (°C) 
 
PEG blend A 
4°C storage 
50.6 + 0.4 - 0.9 
71.8 + 4.2 + 9.4 
56.4 + 0.3 - 1.3 
PEG blend A 
21°C storage 
50.7 + 1.1 - 0.2 
83.8 + 9.0 + 13.3 
57.7 + 0.4 - 0.5 
PEG blend A 
30°C storage 
50.5 - 1.9 - 5.9 
75.3 + 8.8 + 14.5 
56.6 - 0.8 - 5.1 
PEG blend B 
4°C storage 
51.4 + 0.8 - 0.3 
73.4 + 7.3 + 9.1 
57.8 - 0.1 - 1.3 
PEG blend B 
21°C storage  
50.4 + 2.3 + 0.63 
67.2                + 19.2 + 22.8 
56.7 + 1.7 + 0.2 
PEG blend B 
30°C storage 
50.7 + 0.9 - 0.8 
80.1 + 6.1 + 10.9 
57.6 - 0.5 - 1.7 
PEG blend C 
4°C storage 
41.2 + 1.6 + 0.9 
159.4  + 20.4  + 26.5 
50.3 - 0.3 - 0.2 
PEG blend C 
21°C storage  
41.1 - 1.5 - 3.5
165.9 + 6.5 + 9.0 
50.3 - 1.1 - 2.9 
PEG blend C 
30°C storage 
50.0 - 0.7 - 15.3 
164.5 + 6.1 - 8.1 
40.9 - 2.5 + 5.3 
 
 
 
3.4 Infrared Spectroscopy after 1 week, 3 months, 6 months and 12 months.   
 
Infrared spectroscopy utilizes a set of unique peaks on a spectrum which can be used for 
identifying a compound.  Each of the suppository samples was determined by IR 
spectroscopy and added to a compound library.  A percentage match was then performed 
on each sample (table 6).  
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The oxidation of cysteamine to cystamine was the basis of comparisons made between 
samples.  This reaction produces a peak in the region of disulphide bond stretch, i.e. 620-
600 cm-1, and allows a simple identification of sample degradation. 
 
Each suppository was analysed over time using the IR spectrometer, and compared to the 
suppositories at time zero.  The results are shown in table 6 (selected examples only). 
The stability tests using IR analysis demonstrated that PEG blend C was the most stable in 
all conditions, with minimal changes over six months at room temperature and accelerated 
tests, and up to twelve months stability when stored at 4° C.  PEG blend B shows evidence 
of stability over twelve months at room temperature.  PEG blend A shows evidence of 
degradation when subjected to a range of storage conditions, and therefore is unsuitable for 
the rectal delivery of cysteamine. 
 
Table 6.  Suppository stability over time, presented as percentage match to sample at T0 
(selected data only). 
Suppository blend/storage 
conditions 
Percentage match to sample at T0 
PEG blend C, 4°C/8% RH 
 
99.2% at 3 months 
98.84% at 12 months 
PEG blend A, 4°C/8% RH 97.4% at 3 weeks 
PEG blend C, 21°C/52% RH 98.94% at 6 months 
PEG blend B, 21°C/52% RH 97.95% at 12 months 
PEG blend C, 30C/75% RH 98.94% at 6 months 
 
 
3.5 Correlation between DSC plots and IR percentage match results 
 
The IR percentage match data support the DSC plots.  This is evidence of correlation 
between the two methods and allows a more conclusive result to be produced.  For 
example, PEG blend C stored at 21°C displayed a 98.94% match at 6 months (table 6).   
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These stability test results support the hardness testing, and indicate that PEG Blend C was the most 
stable formulation over a 12-month period, and indicate that PEG Blend C was the most stable 
formulation over a 12-month period.  The suppositories stored at 4°C were generally more 
stable than those stored at higher temperatures, although PEG blend C displays long term 
stability even at room temperature.  PEG blend B suppositories were stable over time at 
room temperature.  PEG blend A suppositories displayed long term instability under all 
storage conditions.  PEG blend C displays ideal stability over time in a range of storage 
conditions and is proposed as the optimal formulation in this study. 
  
 
4.0 Conclusions 
 
Liquid gel suppositories containing cysteamine have previously been investigated for the 
treatment of cystinosis (17).  However, due to the osmotic nature of the suppository vehicle, 
the doses were rapidly expelled and cysteamine blood plasma concentrations were 
insufficient to produce a reduction in mean leukocyte cystine concentration.  In this project, 
the suppository bases Witepsol, Gelucire and PEG were investigated for their suitability as 
vehicles for the incorporation of cysteamine hydrochloride and a phenylalanine-cystamine 
conjugate.  Melting point, hardness, stability and appearance were analysed, and the three 
suppository bases with the most suitable characteristics were chosen for further study.  PEG 
blends A, B and C were made and characterised.  Blend C displayed good qualities (i.e. 
complete, reproducible release after 30 minutes, stability over 12 months at 4°C/8% RH) 
required for the delivery of cysteamine hydrochloride to the rectum.  DSC analysis 
indicated that cysteamine hydrochloride was dispersed uniformly in the suppositories.  
Dissolution studies using the phenylalanine-cystamine conjugate revealed 20-60 minute 
release, while cysteamine hydrochloride as the active component demonstrated 17-26 
minute release on average.  The stability tests indicate that 4°C/8% RH provided the ideal 
storage conditions over a 12-month period.  Formulation C was the most stable over time, 
while blend A was the least stable form, and even when stored in the refrigerator was 
subject to degradation.  There was also evidence of an incompatibility between cysteamine 
hydrochloride and PEG Blends A and B, and this may be a combination of physical ageing 
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of the PEG and syneresis of cysteamine (26-29).  There was evidence that crystal ripening 
over time is forcing the expulsion of the cysteamine hydrochloride to the outside surfaces 
of the suppository.  The highly deliquescent cysteamine then quickly dissolves in 
environmental moisture, forming droplets of liquid on the surface of the suppositories.  For 
these reasons, PEG blends A and B would not be suitable for the rectal delivery of 
cysteamine.  Analysis indicates that PEG blend C would be an ideal suppository base for 
the delivery of cysteamine hydrochloride. 
 
These tests demonstrate that cysteamine hydrochloride can be formulated as a suppository, 
and that the bases can tolerate varying amounts of drug loading.  This will be of particular 
benefit when treating cystinosis during infancy, and should allow a significant reduction in 
side effects, improving compliance and morbidity.  In addition, suppositories may help to 
eliminate the overnight treatment break which is difficult to overcome with the oral 
capsules.  Future work with the suppositories will involve the development of in-situ 
gelling forms, and should include in-vivo testing or an in-vitro in-vivo correlation (IVIVC) 
to investigate the potential benefits these forms may have compared to the current oral 
treatment.  
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